for Jan 29, 2019 through Feb 04, 2019
NEW 🔥🔥🔥Just published in @PharmacoJournal @BrianTsuji @jpogue1 @Keith_S_Kaye
— Antibiotic Steward (@ABsteward) February 2, 2019
International Consensus Guidelines for the Optimal Use of the Polymyxins: Recommendations from @ACCP, @ESCMID, @IDSAInfo, @ISAP_org, and @SIDPharm. @SCCM https://t.co/QXKkYamVj6 pic.twitter.com/f5sH0pD2vb
This may be the most chilling sentence I've ever read in a paper:
— Jon Otter (@jonotter) January 30, 2019
"Among the 498 patients [in a Greek ICU], 226 [45%] were rectally colonized by carbapenem-resistant Klebsiella pneumoniae (CRKP), 48 [10% of all patients] of whom developed a CRKP BSI."https://t.co/6BCfNsMKR8
NEW🔥 in CID @Doaa_Aljefri/@IDPharmacometrx/@MPostelnick
— Antibiotic Steward (@ABsteward) February 1, 2019
Vancomycin Area under the Curve and Acute Kidney Injury: A Meta-analysis. https://t.co/tiojuDFPy3 pic.twitter.com/LCZqhFpWCN
Like infectious diseases, ideas in the academic world are contagious. Computer scientists used an epidemiological model to simulate how ideas move from one academic institution to another. https://t.co/BiksjvlTSS
— Scientific American (@sciam) February 1, 2019
Found an interesting article about measles (rubela). It's one of the most infectious diseases in the world, and it's not so much a problem anymore thanks to vaccination.
— Kamal Amzan (@DrKamalAmzan) February 4, 2019
Let's hope that it will stay that way.
8 things everybody should know about measles: https://t.co/0qsZcihsHG pic.twitter.com/yZ37mfy624
NEW 🔥🔥🔥OVIVA finally published :Oral antibiotics non-inferior to intravenous in osteomyelitis. A definite practice-changing study, in @NEJM by @ThwaitesGuy @PhilipBejon @raseaton66 team. VIVA #OVIVA. https://t.co/pStcSOvrxw
— Antibiotic Steward (@ABsteward) January 31, 2019
Great editorial @hboucher3https://t.co/lV7cOUIM0U pic.twitter.com/Eay3WaTbD1
NEW🔥 in CID LEAP 1 Trial Published! Efficacy and Safety of IV-to-Oral Lefamulin, a Pleuromutilin Antibiotic, for Treatment of Community-Acquired Bacterial Pneumonia. https://t.co/4C1gLIiVTU pic.twitter.com/RGCTqmiAKJ
— Antibiotic Steward (@ABsteward) February 4, 2019
Call open for Group Leaders of Junior Research Groups (G5) at @institutpasteur with focus on:
— Björn Meyer (@MeyerBjoern) February 1, 2019
Emerging infectious diseases,
Resistance to antimicrobial agents,
Brain connectivity and Neurodegenerative diseases.https://t.co/LnsCrfnsyR
So much talk about #OVIVA that I made up an "interview" (ahem) with this highly anticipated landmark study. H/T to @PhilipBejon here and Matthew Scarborough for input. Latest post: https://t.co/iH188Vud07
— Paul Sax (@PaulSaxMD) February 3, 2019
NEW in CID 🔥🔥Infectious Diseases Society of America’s 10 × ’20 Initiative (Ten New Systemic Antibacterial Agents FDA-approved by 2020): Is 20 × ’20 a Possibility? @hboucher3 @JasonGNewland https://t.co/IEMEw050GS pic.twitter.com/5N7gmUO5ky
— Antibiotic Steward (@ABsteward) February 1, 2019
Genomics-based study identifies identical antimicrobial resistance genes found in livestock and human isolates, but with limited overlap in the mobile elements carrying these genes @mbiojournal https://t.co/00LJhLFoJ4 pic.twitter.com/cXTNGg0W2u
— ASM (@ASMicrobiology) January 29, 2019
In this study, of the 19 811 patients, Antibiotics were prescribed for 8788 patients (44.4%). Apparently many physicians don't believe this biological reality and this study may be will convince them to. Check this study from 2016 in @JAMA_currenthttps://t.co/eL1h5ixXPJ pic.twitter.com/Okwo1S7LO2
— Antibiotic Steward (@ABsteward) January 29, 2019
Human tumor viruses account for an estimated 12% to 20% of cancers worldwide. The most recent Microbial Sciences article provides a short summary of the pathogenesis, life cycle, and cancers associated with 7 different human viruses https://t.co/kx2BP8rdba
— ASM (@ASMicrobiology) January 31, 2019
It's pretty simple: You prevent measles outbreak by getting the measles vaccine." Let’s all do our part to ensure #VaccinesWork to control & prevent infectious diseases like measles – including right here at home. https://t.co/ML3DKhjHyP
— Keith Klugman (@findingpneumo) January 31, 2019
A biotech company reports that its #bacteriophage therapies have successfully treated patient with relapsing #Staphylococcus aureus prosthetic-joint infection.#Phage therapy could offer an alternative treatment in fight against antimicrobial resistance.https://t.co/7n1rwBl5Rv pic.twitter.com/etAnzxVxBx
— Microbes&Infection (@MicrobesInfect) February 2, 2019
NEW 🔥IMPACT RCT published @TheLancetInfDis
— Antibiotic Steward (@ABsteward) January 30, 2019
Cadazolid for the treatment of Clostridium difficile infection: results of two double-blind, placebo-controlled, non-inferiority, randomised phase 3 trials. https://t.co/Khq4H516b2 pic.twitter.com/LdbEa3UoKv
4 tweetiatricians tried trolling me today for daring to talk about measles and other infectious diseases from the standpoint of vaccine skepticism. They want to shut down all such talk. Meanwhile https://t.co/AGb7S3hIam
— Dr. Rick Kirschner (@DrKND) January 31, 2019
We're thrilled that Prof @BrettBarrettRPh has joined #WaterlooPharmacy as clinical lecturer. In this role she will deliver infectious disease & antimicrobial stewardship parts of the PharmD program & will also oversee the institutional practice components https://t.co/8bCzUrPeh1
— Waterloo Pharmacy (@UWPharmacy) January 29, 2019
A succinct (and free text) summary of Antimicrobial Stewardship in hospitals over 20 years by @e_charani el al. Great references contained within too https://t.co/j92j3KjFxy @AntibioticLeeds @EmmaCramp @TingYauMRPharmS pic.twitter.com/cxWUhZVJJe
— David Ladenheim (@ladenheimd) January 29, 2019
First clinical trial for intravenous phage therapy gets FDA approval - Infectious Diseases Hub https://t.co/BiXICEtES0
— Adam P Roberts (@GCAGATGCAATG) February 2, 2019
Our Aussie colleagues published a meta-analysis in JAC concluding “ASPs involving #pharmacists are effective in decreasing #antibiotic prescribing and increasing guideline-adherent antibiotic prescribing by GPs”. 👏🏼 Team work makes the dream work! https://t.co/lXX2TI5OeK
— Lauren Hunt (@LNHsteward) January 30, 2019
NEW🔥🔥 in CMI @jesusrbano et Al @ESCMID-EUCIC clinical guidelines on decolonisation of multidrug-resistant Gram-negative bacteria carriers. https://t.co/Ea1THsJKiY pic.twitter.com/MOyvauxD3z
— Antibiotic Steward (@ABsteward) January 31, 2019
In search of microbes from > 1,400 insects collected from diverse environments, researchers found that insect-borne microbes often outperform soil bacteria in stopping some of most common & dangerous antibiotic-resistant pathogens.https://t.co/RFuoSQYooy #AntibioticResistance pic.twitter.com/kkYl8p4EGD
— Microbes&Infection (@MicrobesInfect) February 4, 2019
PUBLISHED: second “UK One Health Report – Joint report on antibiotic use and antibiotic resistance, 2013-2017”:https://t.co/MPFnIIskpE#KeepAntibioticsWorking #AntibioticGuardian pic.twitter.com/VX1JUgKUyA
— Diane Ashiru, PhD (@DrDianeAshiru) January 31, 2019
The state of #education and training for healthcare professionals on -#antimicrobialstewardship in Indian #hospitals - pleased to see this published in the special issue of #Antibiotics guest edited by @HelenSLambert @ProfRichSmith @MDPIOpenAccess https://t.co/FG2gZWDxE1 pic.twitter.com/4bp2hDzIOa
— Esmita Charani (@e_charani) January 30, 2019
Excellent editorial on POET and OVIVA by @hboucher3. Appreciate the mention of a multidisciplinary approach to complex infections including pharmacists. Partial Oral Therapy for Osteomyelitis and Endocarditis — Is It Time? | NEJM https://t.co/ogWVQnp0BI
— Chris Bland (@blandman19) January 31, 2019
We are thrilled to see that The Interagency Coordination Group on Antimicrobial Resistance have published their draft recommendations and are hosting a public consultation for feedback.
— AMR at Wellcome (@Wellcome_AMR) January 29, 2019
Read the recommendations and find out how to provide feedback here👇 https://t.co/rn3d9R2Dg2
Competition in biofilms between CF isolates of P. aeruginosa is shaped by R-pyocins, which have potential as antimicrobial and antibiofilm agents @mbiojournal https://t.co/Unj5Dqed3Q pic.twitter.com/54hhy5DExL
— ASM (@ASMicrobiology) February 4, 2019
The measles virus is one of the most infectious diseases known to man. @voxdotcom outline eight things you need to know 💡 https://t.co/3Urom9NhLF #VaccinesWork pic.twitter.com/5fteDEW6L1
— Wellcome Trust (@wellcometrust) February 1, 2019
Great article providing guidance to pharmacists on implementing penicillin skin testing- PharmDs in our state cant admin test itself 😔 but we are working with our Allergy friends to get something going soon! Such an important stewardship tool!https://t.co/WihuIqYKwV
— UChicago ASP (@chicagoabx) January 31, 2019
Novel routes to obtaining antibiotics, which bypass face to face medical assessment, undermine antimicrobial stewardship strategies, and are likely to increase inappropriate use. Our editorial in @BJGPjournal https://t.co/YDiBrqXggu
— Benedict Hayhoe (@BenedictHayhoe) February 1, 2019
Watch how the #measles outbreak spreads when kids get vaccinated – and when they don'thttps://t.co/eOf7IA8hqT
— Microbes&Infection (@MicrobesInfect) February 2, 2019
Use of microbiology tests in the era of increasing AMR rates– a multicentre hospital cohort study @BSkodvin @HPRUamr @ARC_at_Imperial https://t.co/SCokgreIi0 #aricjournal
— Esmita Charani (@e_charani) February 4, 2019
#AntibioticGuardian awards: recognising efforts by organisations & individuals to tackle antimicrobial resistance through #improveIPC and #KeepAntibioticsWorking in the UK & abroad. #EAAD #StopSuperBugs. https://t.co/m1cnc1o88H cc @CMO_England @keithridge1 @RMayNurseDir @CSOSue pic.twitter.com/nZlRSnovD2
— Diane Ashiru, PhD (@DrDianeAshiru) February 1, 2019
Great new Pediatric #AntimicrobialStewardship toolkit from @PIDSociety; covers both inpatient/ outpatient settings! https://t.co/7ofJRC3Tu9 pic.twitter.com/UHLkjnA5aN
— Mike Stevens (@Dr_Mike_Stevens) January 31, 2019
Which competencies do you need for antimicrobial prescribing and stewardship?https://t.co/jZbCdlP6lL
— Leonard Leibovici (@LeonardLeibovi1) February 1, 2019
Are you a #Medic with experience in designing, delivering and evaluating #interventions to reduce #infections and #antimicrobialresistance (#AMR)? Come work with us @PHE_uk - closes Feb 9 - open to any relevant speciality - #ID #Micro #GP #PH #generalist https://t.co/gCa2wYyJg0 pic.twitter.com/oSeUCydR2V
— Susan Hopkins (@SMHopkins) January 29, 2019
Giving talk to @EmoryMedicine ID colleagues at faculty retreat about social media and why Twitter is useful professionally to encourage them to join. Got some great ideas from @KellyCawcuttMD recent talk as well as from a CID paper https://t.co/hpKwuHwvjD. Anything else?
— Carlos del Rio (@CarlosdelRio7) January 31, 2019
A gut punch fights #cancer and infection.
— Microbes&Infection (@MicrobesInfect) February 2, 2019
Study reports the identification of 11 strains of bacteria that reside in the guts of some healthy humans & can boost immune responses that fight #infection & cancer.https://t.co/sAm5N9MRlU #microbiota #immunity pic.twitter.com/SgaEGVACOZ
Free access to our article on the impact of #AntimicrobialStewardship with rapid respiratory diagnostic testing in @AJICJournal: https://t.co/GARTsEIrn7
— Mike Stevens (@Dr_Mike_Stevens) January 30, 2019
“…the right of anti-vaxxers to be sick ends where the public’s right to health begins.” Powerful words from leaders at @ACSHorg in response to the measles outbreak in Washington. @Newsweek https://t.co/l3vYwIvbka
— IDSA (@IDSAInfo) January 30, 2019
📄🔬🧫
— Bug Pharmacist (@IDstewardship) January 31, 2019
New! In JCM @romneyinla and colleagues publish their work on #colistin sensitivity testing and a commentary is provided... via @JClinMicro and @ASMicrobiology #BackToTheFuture
Commentary 📲 https://t.co/VS37F5Q6hu
Article 📲 https://t.co/OFPtdrz4Fn pic.twitter.com/bSqYx0EGmi
“The measles virus is one of the most infectious diseases known to man.” How government leniency & vaccine refusals have led to the latest outbreak of #measles: @juliaoftoronto for @voxdotcom, with comments from @PeterHotez. https://t.co/G5xyKgwsZ4 #VaccinesWork
— Global Health Strategies (@GHS) January 31, 2019
Ceftaroline Fosamil for the Treatment of Gram-Positive Endocarditis: CAPTURE Study Experience JUST 🔥Published in IJAA. @Keith_S_Kayehttps://t.co/IDvksxURbM pic.twitter.com/IGDN0MziHJ
— Antibiotic Steward (@ABsteward) January 31, 2019
Measles Outbreak Worsens in Washington State, US.
— Microbes&Infection (@MicrobesInfect) January 29, 2019
Most of the 34 patients are under 10 years old, and almost all have been confirmed as unvaccinated against the virus.https://t.co/2iKdHFdr9l #measles #VaccinesWork #antivax pic.twitter.com/HgmCRp4bJL
Presenting CATCH, our algorithm to design compact & comprehensive probe sets for microbial genome recovery with @haydenmetsky, now online in @NatureBiotech! Our 356-virus panel increases sensitivity and lowers costs for surveillance of infectious diseases. https://t.co/6RlGdo8FLI https://t.co/WmCK8iEomo
— Katherine Siddle (@kjsiddle) February 4, 2019
'Promising R&D projects risk dying on the vine for lack of finance.' Read Jeremy Knox's piece on why the new UK antibiotic financing strategy is a great first step, but faster and more ambitious action is required for sustainable antibiotic development ➡️https://t.co/GVZkq1YCyc
— AMR at Wellcome (@Wellcome_AMR) January 30, 2019
Oral versus Intravenous Antibiotics for Bone and Joint Infection | Nice to see the OVIVA trial published in @NEJM Oral antibiotics were non inferior to IV antibiotics in the Rx of osteomyelitis. Time to give up the PICC line? @jaybvarkey https://t.co/hjWCJhyrtd
— Carlos del Rio (@CarlosdelRio7) January 30, 2019
New online> Cadazolid for the treatment of #Clostridium difficile infection: results of two double-blind, placebo-controlled, non-inferiority, randomised phase 3 trials https://t.co/wWwhSA8gOA #Cdiff
— The Lancet Infectious Diseases (@TheLancetInfDis) January 30, 2019
Are IPC link nurses worth it? This review finds a lack of evidence, but promotes the concept https://t.co/R3sr6CpXIm #aricjournal @ARICJournal
— Jon Otter (@jonotter) February 1, 2019
This @CJASN article explores the clinical and economic benefits of #antimicrobial stewardship programs in #dialysis facilities | https://t.co/8QbgWVYuHz #ASN_NTDS #TargetZeroInfections pic.twitter.com/E50hOQ8elS
— Am Soc Nephrology (@ASNKidney) January 29, 2019
Created by Cameron Forbes. Last updated February 19, 2019 at 05:13 EST.